Gamco Investors INC. ET AL cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 2.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,519 shares of the medical research company’s stock after selling 5,000 shares during the period. Gamco Investors INC. ET AL owned approximately 0.23% of NeoGenomics worth $2,924,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the second quarter valued at about $171,000. AMP Capital Investors Ltd acquired a new stake in shares of NeoGenomics during the second quarter valued at about $178,000. PNC Financial Services Group Inc. acquired a new stake in shares of NeoGenomics during the second quarter valued at about $272,000. Howland Capital Management LLC increased its position in shares of NeoGenomics by 39.8% during the third quarter. Howland Capital Management LLC now owns 30,449 shares of the medical research company’s stock valued at $467,000 after acquiring an additional 8,667 shares during the last quarter. Finally, Cornerstone Wealth Management LLC acquired a new stake in shares of NeoGenomics during the second quarter valued at about $528,000. 82.37% of the stock is currently owned by institutional investors.

Shares of NEO stock opened at $16.63 on Tuesday. The company has a quick ratio of 3.98, a current ratio of 4.13 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $1.58 billion, a P/E ratio of 277.17 and a beta of -0.01. NeoGenomics, Inc. has a fifty-two week low of $7.08 and a fifty-two week high of $19.04.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $69.10 million during the quarter, compared to analysts’ expectations of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. The business’s quarterly revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 earnings per share. As a group, research analysts predict that NeoGenomics, Inc. will post 0.11 EPS for the current year.

A number of equities research analysts have weighed in on NEO shares. Leerink Swann initiated coverage on shares of NeoGenomics in a research report on Tuesday, August 21st. They set an “outperform” rating and a $18.00 price target for the company. Craig Hallum lifted their price objective on shares of NeoGenomics from $17.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Zacks Investment Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective for the company in a report on Saturday, November 3rd. First Analysis set a $16.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a report on Tuesday, September 18th. Finally, BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 10th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the stock. NeoGenomics has a consensus rating of “Buy” and an average target price of $20.00.

ILLEGAL ACTIVITY WARNING: “Gamco Investors INC. ET AL Has $2.92 Million Holdings in NeoGenomics, Inc. (NEO)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/13/gamco-investors-inc-et-al-has-2-92-million-holdings-in-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Read More: What Factors Can Affect Return on Equity?

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.